Search Result

Results for "

left ventricular

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (4) Angiotensin-converting Enzyme (ACE) (3) Anion Exchangers (1) Antibiotic (1) Apoptosis (3) Calcium Channel (3) Carbonic Anhydrase (1) Caspase (1) Cathepsin (1) DNA Alkylator/Crosslinker (1) Elastase (1) Endogenous Metabolite (2) Endothelin Receptor (1) Eukaryotic Initiation Factor (eIF) (2) Glutathione Peroxidase (2) Isotope-Labeled Compounds (3) Lipoxygenase (1) MMP (3) Myosin (3) Na+/H+ Exchanger (NHE) (1) NADPH Oxidase (1) Neprilysin (1) NO Synthase (2) Phosphodiesterase (PDE) (1) PKC (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (10) PPAR (1) Reference Standards (4) SOD (1) Sodium Channel (1) TGF-beta/Smad (1) Topoisomerase (1) TRP Channel (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (44) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Adenosine Receptor (1)

Adrenergic Receptor (4)

Angiotensin-converting Enzyme (ACE) (3)

Anion Exchangers (1)

Antibiotic (1)

Apoptosis (3)

Calcium Channel (3)

Carbonic Anhydrase (1)

Caspase (1)

Cathepsin (1)

DNA Alkylator/Crosslinker (1)

Elastase (1)

Endogenous Metabolite (2)

Endothelin Receptor (1)

Eukaryotic Initiation Factor (eIF) (2)

Glutathione Peroxidase (2)

Isotope-Labeled Compounds (3)

Lipoxygenase (1)

MMP (3)

Myosin (3)

Na+/H+ Exchanger (NHE) (1)

NADPH Oxidase (1)

Neprilysin (1)

NO Synthase (2)

Phosphodiesterase (PDE) (1)

PKC (1)

Platelet-activating Factor Receptor (PAFR) (1)

Potassium Channel (10)

PPAR (1)

Reference Standards (4)

SOD (1)

Sodium Channel (1)

TGF-beta/Smad (1)

Topoisomerase (1)

TRP Channel (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (44)

Inflammation/Immunology (3)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112654

GCN2iB Maximum Cited Publications 60 Publications Verification	Eukaryotic Initiation Factor (eIF) Glutathione Peroxidase	Cardiovascular Disease Metabolic Disease Cancer
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC₅₀ of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .

HY-B0259

Indapamide 1 Publications Verification	Potassium Channel	Cardiovascular Disease
Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-101415

Coenzyme Q9 1 Publications Verification Ubiquinone Q9; CoQ9; Ubiquinone 9	Apoptosis Endogenous Metabolite	Cardiovascular Disease
Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .

HY-119850

Aladorian ARM036; S44121	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian improves cardiomyocyte Ca²⁺ homeostasis independent of dystrophin restoration. Aladorian attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-159821

Ulacamten CK-4021586; CK-586	Myosin	Cardiovascular Disease
Ulacamten (CK-4021586; CK-586) is an orally active cardiac myosin inhibitor and an inhibitor of the double-headed cardiac heavy meromyosin (HMM)ATPase (excluding single-headed myosin subfragment-1), with an EC₅₀ of 2.9 μM. Ulacamten regulates cardiac myosin, reduces excessive myocardial contractility, and alleviates left ventricular outflow tract obstruction. Ulacamten increases the left ventricular short-axis systolic internal diameter, inhibits dobutamine-induced exacerbation of obstruction, and exerts only a mild reducing effect on left ventricular systolic function. Ulacamten also inhibits the fractional shortening of the short axis without altering calcium transients. Ulacamten shows good safety and tolerability in purpose-bred cats with naturally occurring obstructive hypertrophic cardiomyopathy .

HY-106369

HMR 1556 2 Publications Verification	Potassium Channel	Cardiovascular Disease
HMR 1556, a chromanol derivative, is a potent I_Ks blocker with IC₅₀s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively .

HY-174374

Topobexin	Topoisomerase	Cardiovascular Disease
Topobexin is a TOP2B-selective inhibitor with IC₅₀ values of 0.19 μM and 4.8 μM for TOP2B and TOP2A (DNA decatenation assay). Topobexin binds to non-homologous residues in the obex pocket and targets the ATPase domain of TOP2B. Topobexin prevents anthracycline-induced DNA double-strand break formation, apoptotic signaling mediated by caspase 3/7, 8 and 9, cardiomyocyte morphological changes, mitochondrial depolarization/loss, left ventricular systolic dysfunction, extracellular matrix remodeling, fibrotic alterations, and increases in plasma cardiac troponin T and BNP. Topobexin does not impair the antiproliferative effects of anthracyclines in cancer cells, exhibits no intrinsic cytotoxicity in cardiomyocytes, and is well tolerated in rabbits. Topobexin can be used in studies related to anthracycline-induced cardiotoxicity .

HY-100634

4-Hydroxypropranolol hydrochloride (±)-4-hydroxy Propranolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
4-Hydroxypropranolol hydrochloride is a non-cardiac selective β-adrenergic receptor antagonist and a metabolite produced after oral administration of Propranolol (HY-B0573B). 4-Hydroxypropranolol hydrochloride also acts as a membrane stabilizer and possesses intrinsic sympathomimetic inhibitory activity. 4-Hydroxypropranolol hydrochloride blocks β-adrenergic receptors to antagonize the effects of catecholamines, acts as a partial β-adrenergic receptor agonist, and induces membrane stabilization. 4-Hydroxypropranolol hydrochloride alters heart rate, left ventricular contractility, and atrioventricular conduction time. 4-Hydroxypropranolol hydrochloride can be used in research related to cardiovascular and cerebrovascular diseases .

HY-W042301

Xipamide	Anion Exchangers Carbonic Anhydrase Endothelin Receptor	Cardiovascular Disease
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na ⁺/Cl ^--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl ^-/NaCO₃ ^- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca ²⁺ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .

HY-148804

Vemtoberant APD418	Adrenergic Receptor	Cardiovascular Disease
Vemtoberant is a β₃-adrenergic receptor inhibitor with a human K_i of 8.2 nM, and exhibits 400- to 600-fold selectivity over human β₁-AR and β₂-AR. Vemtoberant attenuates β₃-AR-mediated cardiac inhibition. Vemtoberant can be used for the research of systolic heart failure .

HY-106844A

(+)-EMD 57033	Phosphodiesterase (PDE)	Cardiovascular Disease
(+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca ²⁺ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .

HY-108448

N-Oleoyldopamine OLDA	TRP Channel Lipoxygenase	Cardiovascular Disease Neurological Disease Metabolic Disease
N-Oleoyldopamine (OLDA) is an orally active TRPV1 activator and 5-LOX inhibitor with blood-brain barrier permeability. N-Oleoyldopamine excites histaminergic neurons in the tuberomammillary nucleus via a dopamine receptor mechanism, a process independent of TRPV1 and cannabinoid receptors. On one hand, N-Oleoyldopamine promotes the release of insulin and glucose-dependent insulinotropic polypeptide through a GPR119-dependent pathway to improve glucose tolerance; on the other hand, N-Oleoyldopamine improves left ventricular function and reduces myocardial infarction size by triggering the release of substance P and calcitonin gene-related peptide. N-Oleoyldopamine is used in studies related to glycemic abnormalities and myocardial ischemia-reperfusion injury .

HY-107428

PD-166793	MMP	Cardiovascular Disease
PD-166793 is a potent, selective, orally active and wide-broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC₅₀=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC₅₀=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure .

HY-172424

Delocamten	Myosin	Cardiovascular Disease
Delocamten is the inhibitor for cardiac myosin with an IC₅₀ of 1.1 μM. Delocamten can be used in researchs of hypertrophic cardiomyopathy, left ventricular hypertrophy and diastolic dysfunction .

HY-101415R

Coenzyme Q9 (Standard) Ubiquinone Q9 (Standard); CoQ9 (Standard); Ubiquinone 9 (Standard)	Reference Standards Apoptosis Endogenous Metabolite	Cardiovascular Disease
Coenzyme Q9 (Standard) is the analytical standard of Coenzyme Q9. This product is intended for research and analytical applications. Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis .

HY-121460

Spiraprilat	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Spiraprilat is a potent angiotensin-converting enzyme (ACE) inhibitor. Spiraprilat has ability to improve left ventricular (LV) function and metabolism in anesthetized open-chest dogs with acute ventricular failure (ALVF) .

HY-173517

NHE-1-IN-2	Na+/H+ Exchanger (NHE)	Neurological Disease
NHE-1-IN-2 (compound 7g) is a potent NHE-1 inhibitor with an IC₅₀ of 0.78 μM. NHE-1-IN-2 alleviates left ventricular systolic dysfunction in mice model of heart failure .

HY-114683

KS370G	TGF-beta/Smad	Cardiovascular Disease
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy .

HY-119817

Flosequinan BTS 49465; Flosequinon	PKC	Cardiovascular Disease
Flosequinan is a balanced vasodilator. Flosequinan not only significantly reduces systemic vascular resistance, but also significantly reduces the beating component of left ventricular afterload, characteristic impedance and arterial wave reflection, which can be used in the research of acute heart failure .

HY-B0259R

Indapamide (Standard) 1 Publications Verification	Reference Standards Potassium Channel	Cardiovascular Disease
Indapamide (Standard) is the analytical standard of Indapamide. This product is intended for research and analytical applications. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-163120

Myosin-IN-1	Myosin	Cardiovascular Disease
Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiac myosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiac myosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research .

HY-171888

BI-9740	Cathepsin Elastase	Inflammation/Immunology
BI-9740 is an orally active and selective cathepsin C (CatC) inhibitor, with an IC₅₀ of 0.6 nM in mice and 2.6 nM in rats. BI-9740 can inhibit the production of active neutrophil elastase. Additionally, BI-9740 is capable of reducing the activities of neutrophil elastase and cathepsin G in the bone marrow of rats, alleviating pathological damage to grafts after heart transplantation, shortening the reperfusion time, and improving left ventricular function. BI-9740 can be used in research related to organ transplantation .

HY-130579

Vinyl-L-NIO hydrochloride L-VNIO hydrochloride	NO Synthase NADPH Oxidase	Cardiovascular Disease Neurological Disease
Vinyl-L-NIO (L-VNIO) hydrochloride is a neuronal nitric oxide synthase (NOS) inhibitor with a rat K_i of 0.10 μM. Vinyl-L-NIO hydrochloride inhibits NADPH oxidase activity, attenuates renal fibrosis, inflammation, oxidative stress indices, and albuminuria. Vinyl-L-NIO hydrochloride can be used for the research of parkinson's disease, migraine headache, and hypertension .

HY-116478

L-3373	Potassium Channel	Others
L-3373 is a voltage-dependent potassium channel inhibitor with activity that reduces the effective refractory period and the dispersion of monophasic action potential duration, while significantly reducing susceptibility to ventricular fibrillation in a cat model of left ventricular hypertrophy.

HY-14240

PG 116800 PG 530742; PGE 530742; PGE 7113313	MMP	Cardiovascular Disease
PG 116800 (PGE 530742; PGE 7113313) is an orally active, selective and high-affinity inhibitor of MMP. PG 116800 acts as an inhibitor of ventricular remodeling, reduces left ventricular volumes and infarct zone collagen content, and improves ejection fraction. PG 116800 is generally well tolerated, but is associated with higher rates of arthralgia, joint stiffness, and dyspepsia. PG 116800 can be used for the research of myocardial infarction .

HY-B0259S

(rac)-Indapamide-d3	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease
(rac)-Indapamide-d₃ is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-P11297

AC-SDKP-NH2	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research .

HY-B0259A

Indapamide hemihydrate	Potassium Channel	Cardiovascular Disease
Indapamide hemihydrate is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide hemihydrate is also can reduce left ventricular hypertrophy .

HY-Y1150

Pivalic acid Trimethylmethanecarboxylic acid; Versatic 5 acid; tert-Pentanoic acid	Antibiotic	Inflammation/Immunology
Pivalic acid (Trimethylmethanecarboxylic acid) is a carboxylic acid. Pivalic acid induces Carnitine deficiency. Pivalic acid conjugated with Antibiotics, such as Pivmecillinam (HY-B0810) and Pivampicillin (HY-119011), are used in urinary tract infection. Pivalic acid can be used in physical exercise research .

HY-120355

AP14145	Potassium Channel	Cardiovascular Disease
AP14145 is an inhibitor for small conductance calcium-activated potassium channel, inhibits K_Ca2.2 channel and K_Ca channel with IC₅₀ of 1.1 μM and 1.1 μM. AP14145 prolongs atrial effective refractory period (AERP) in rats, causes the conversion of atrial fibrillation to sinus rhythum in porcine left ventricular dysfunction models, and exhibits antiarrhythmic effect .

HY-106024A

Alagebrium bromide ALT711 bromide	DNA Alkylator/Crosslinker	Cardiovascular Disease
Alagebrium bromide is an analog of Alagebrium Chloride (HY-106024B), a glucose cross-link blocker. Alagebrium Chloride disrupts glucose cross-links and may improve ventricular and arterial compliance. Alagebrium Chloride improves left ventricular diastolic filling and has the potential to inhibit diastolic heart failure (DHF).

HY-129782

SC-55858	SOD	Cardiovascular Disease
SC-55858 is an effective superoxide dismutase simulator. SC-55858 increased heart rate and decreased mean arterial pressure and left ventricular systolic and end-diastolic pressures in conscious dogs .

HY-116119

BDF 9148	Sodium Channel	Cardiovascular Disease
BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure .

HY-19121

TCV-309	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
TCV-309 is an antagonist for platelet activating factor (PAF). TCV-309 improves the left ventricular function during ischemia-reperfusion (77.6% recover at 1 μM), protects the cardiac function .

HY-120298

LY-510929	PPAR	Others
LY-510929 is a compound that induces left ventricular hypertrophy (LVH). Related studies have identified the relevant conditions in which LY-510929 may induce LVH by measuring multiple markers and using multiple techniques.

HY-B0259S3

Indapamide-d6	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease
Indapamide-d6 is a deuterated labeled Indapamide . Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-W722221

Colterol acetate	Adrenergic Receptor	Cardiovascular Disease
Colterol acetate is a selective inhibitor of β-adrenergic receptors. Colterol acetate can relax tracheal smooth muscle (primarily acting on β2 receptors), reduce subspastic contractions of tricholoma (acting on β2), and increase contractility of left ventricular papillary muscles (acting on β1) .

HY-B0259S1

Indapamide-13C,d3	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease
Indapamide- ¹³C,d₃ is ¹³C and deuterium labeled Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-129706

LY127210 free base	Others	Cardiovascular Disease
LY127210 (free base) is a potent vasodilator with antihypertensive effects that reduces pressure in chloralose-anesthetized spontaneously hypertensive rats primarily by direct arteriolar dilation and to a lesser extent by decreasing cardiac output. LY127210 (free base) reduces blood pressure, heart rate and left ventricular end-diastolic pressure in hypertensive rats by reducing vascular resistance .

HY-119850A

Aladorian sodium ARM036 sodium; S44121 sodium	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) sodium is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian sodium stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian sodium improves cardiomyocyte Ca ²⁺ homeostasis independent of dystrophin restoration. Aladorian sodium attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian sodium can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-106987

SP/W 5186	NO Synthase	Cardiovascular Disease Inflammation/Immunology
SP/W-5186 is a nitric oxide (NO) donor agent containing a cysteine structure. SP/W-5186 can improve cardiac function, reduce myocardial damage, protect vascular endothelial function and inhibit inflammation and oxidative stress. SP/W-5186 has the ability to inhibit oxidative damage induced by peroxynitrite (ONOO⁻). SP/W-5186 can be used in the research of myocardial ischemia-reperfusion injury .

HY-112654A

GCN2iB acetate	Eukaryotic Initiation Factor (eIF) Glutathione Peroxidase	Cardiovascular Disease Metabolic Disease Cancer
GCN2iB acetate is an ATP-competitive, selective GCN2 inhibitor with an IC₅₀ of 2.4 nM. GCN2iB acetate inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB acetate enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB acetate increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB acetate can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .

HY-120257

IDN-1965	Caspase Apoptosis	Cardiovascular Disease
IDN-1965 is an irreversible, broad-spectrum caspase inhibitor. IDN-1965 prevents downstream apoptotic events (such as DNase activation) and significantly delays cytochrome c release by inhibiting caspase activity. IDN-1965 significantly delayed death in mice with cardiomyocyte apoptosis. IDN-1965 completely prevents left ventricular dilation, systolic dysfunction, and fibrosis in mice with dilated cardiomyopathy. IDN-1965 can be used to study apoptosis-related diseases such as heart failure and the mechanisms of apoptosis initiation .

HY-118264

MDL-100240	Angiotensin-converting Enzyme (ACE) Neprilysin	Cardiovascular Disease
MDL-100240 is a dual-acting angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. MDL-100240 can significantly lower blood pressure, reverse left ventricular hypertrophy, and effectively prevent hypertrophy and dilatation of the aorta and resistance arteries, with an effect comparable to that of ramipril (HY-B0279). In addition, MDL-100240 can also reduce aldosterone levels, but has no significant effect on atrial natriuretic peptide and cGMP. In 3-month-old transgenic rats, MDL-100240 can reduce adrenomedullin concentrations, prevent and reverse severe hypertension and cardiovascular damage, and enhance bradykinin effects.

HY-118991

KT-1	Adenosine Receptor	Cardiovascular Disease
KT-1 is a vasodilator. KT 1 can decrease aortic pressure, renal blood flow, left ventricular enddiastolic pressure and resistances of total peripheral, vertebral, coronary and renal vasculatures and increase aortic blood flow, vertebral blood flow, coronary blood flow, peak positive left ventricular dP/dt and heart rate in anesthetized open-chest dogs. KT-1 can be used for the research of cardiovascular disease .

HY-107428R

PD-166793 (Standard)	Reference Standards MMP	Cardiovascular Disease
PD-166793 (Standard) is the analytical standard of PD-166793 (HY-107428). This product is intended for research and analytical applications. PD-166793 is a potent, selective, orally active and wide-broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC₅₀=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC₅₀=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure .

HY-106458

Niludipine Bay a 7168	Calcium Channel	Cardiovascular Disease
Niludipine (Bay a 7168) is an orally active calcium channel blocker and vasodilator with antihypertensive effects. Niludipine can improve early fatal ventricular arrhythmias induced by acute myocardial ischemia in rats. Niludipine can reduce left ventricular systolic and diastolic loads during pacing-induced angina pectoris. Niludipine can be used in the research of cardiovascular diseases such as coronary heart disease and myocardial ischemia .

HY-106369R

HMR 1556 (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease
HMR 1556 (Standard) is the analytical standard of HMR 1556 (HY-106369). This product is intended for research and analytical applications. HMR 1556, a chromanol derivative, is a potent IKs blocker with IC₅₀s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively .

HY-183859

H142/08	Adrenergic Receptor	Cardiovascular Disease
H142/08 is a β1-adrenergic receptor-selective agonist. H142/08 induces concentration-dependent relaxation of isolated rat uterus and acts as a chronotropic stimulant to increase atrial rate, and its effects are effectively antagonized by Pafenolol (HY-165495). H142/08 also antagonizes the chronotropic effect of isoproterenol on isolated rat right atrium, but requires a higher proportion of receptor occupancy to produce sufficient stimulatory effects .

Cat. No.	Product Name	Target	Research Area